DA-2811 vs. Farxiga: Which Diabetes Treatment Proves More Effective in 2026?
Dong-A ST revealed on Monday that it presented findings from a clinical trial comparing its SGLT-2 inhibitor diabetes treatment, DA-2811 (brand name Dapapro), with Farxiga at the American Diabetes Association (ADA) Scientific Sessions.At the poster p